Our Science

The main diseases of ageing are:

Vascular system heart attack, stroke, hypertension
Brain  Alzheimer’s and Parkinson’s Diseases, dementia
Lung COPD (Chronic Obstructive Pulmonary Disease), chronic asthma
Kidney chronic kidney disease
Joints arthritis
Eye macular degeneration, cataract, glaucoma, retinopathy
Cancer any part of the body.

These are all complex diseases where an individual disease involves the malfunctioning of dozens of different genes, and therein lies the problem. Treatment for any ONE of these diseases means having to correct the misbehaviour of dozens of genes, which is why modern medicine is struggling to offer any meaningful relief because of the modern trend to design drugs that target single genes.

Filamon has deliberately progressed in the opposite direction and through an iterative deep learning process researched drugs that work on multiple genes. With the assistance of leading medical scientists, we have discovered two drugs that modify the activity of multiple genes. Rather than targeting individual genes, the target of these drugs is a small number of gene transcription factors each of which in turn regulates the activity of hundreds of genes. Importantly the two current Filamon drugs do so without compromising patient safety because their effect is directed mainly at genes that are malfunctioning.

Two current Filamon drugs, KS-c2 and LK-BT2, both proprietary to Filamon and which we believe both offering a revolutionary way to treat complex degenerative diseases of aging.


A cyclic peptide with three main functions – inhibition of

  • the enzyme, sPLA2-hGIIA (non-catalytic functions only)
  • activation by sPLA2-hGIIA of the microfilament, vimentin
  • activation by growth factors of the receptor, EGFR.


A small molecule working through MEK1ERK1/2AP1 (FosB and cJun) axis to modify the behaviour of multiple genes including VEGFs, VCAM-1, ICAM-1, IL-6, IL-1b, CXCL-1, CXCL-3, CXCL-8 and CCL-20.

Filamon believes that complex diseases of ageing need complex-acting drugs.